gemcitabine has been researched along with busulfan in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 19 (47.50) | 29.6817 |
| 2010's | 16 (40.00) | 24.3611 |
| 2020's | 4 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
| Thigpen, T | 1 |
| Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT | 1 |
| Bamberg, M; Dichgans, J; Duffner, F; Hermisson, M; Kortmann, RD; Küker, WM; Weller, M; Wick, W | 1 |
| Corrie, PG; Cree, IA; Haass, N; Hengge, U; Kuwert, C; Neuber, K; Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Zutt, M | 1 |
| Becker, JC; Bröcker, EB; Terheyden, P | 1 |
| Bechrakis, N; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, J; Thiel, E | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Cree, IA; Kurbacher, CM; Neale, MH; Reinhold, U | 1 |
| Bulusu, R; Corrie, PG; Cree, IA; Hartley, JA; Jonson, A; Mayer, A; Sehmbi, R; Shaw, J; Spanswick, VJ | 1 |
| Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Martus, P; Schmidt-Hieber, M; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| Bodo, J; Duraj, J; Rauko, P; Sedlak, J; Sulikova, M | 1 |
| Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 3 |
| Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Bassett, R; Champlin, R; Chancoco, C; Ciurea, S; Frazier, E; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Thall, P; Valdez, B; Worth, L | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Champlin, R; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Liu, P; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Valdez, B | 1 |
| Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Murray, D; Nieto, Y; Valdez, BC | 1 |
| Galvez-Silva, J; Hernandez, F; Liu, D; Maher, OM; Nieto, Y; Park, M; Tewari, P | 1 |
| Gahrton, G | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
| Andersson, BS; Bashir, Q; Li, Y; Liu, Y; Murray, D; Nieto, Y; Qazilbash, MH; Valdez, BC | 1 |
| Garri, DD; Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tsygankov, АY | 1 |
| Chen, X; Dong, T; Ji, J; Kuang, P; Li, J; Liu, J; Liu, T; Liu, Z; Shen, K; Zhang, C; Zhang, L | 1 |
| Armand, P; Fisher, DC; Jacobsen, ED; Jacobson, C; Jeter, E; Kim, HT | 1 |
2 review(s) available for gemcitabine and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
14 trial(s) available for gemcitabine and busulfan
| Article | Year |
|---|---|
Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoadjuvant Therapy; Venous Thrombosis | 2002 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pilot Projects; Survival Analysis; Uveal Neoplasms | 2003 |
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome; Uveal Neoplasms | 2004 |
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Treatment Outcome; Uveal Neoplasms | 2004 |
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Uveal Neoplasms | 2005 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leukopenia; Male; Melanoma; Middle Aged; Survival Analysis; Thrombocytopenia; Uveal Neoplasms | 2005 |
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 2005 |
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Uveal Neoplasms | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Recurrence; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Radionuclide Imaging; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Vorinostat | 2015 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
24 other study(ies) available for gemcitabine and busulfan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Treatment Failure | 2002 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Treosulfan and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Humans; Melanoma; Reproducibility of Results; Uveal Neoplasms | 2005 |
Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Cycle; Cell Line, Tumor; Cycloheximide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Leukemia; Paclitaxel; Resveratrol; Stilbenes | 2006 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Uveal Neoplasms | 2008 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan | 2010 |
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cytotoxins; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Lymphoma; Melphalan; Protein Serine-Threonine Kinases; Transplantation Conditioning; Transplantation, Homologous; Tumor Suppressor Proteins | 2012 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2014 |
Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cladribine; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Hematopoietic Stem Cell Transplantation; Histones; Humans; Hydroxamic Acids; Intracellular Membranes; Lymphoma; Mitochondria; Signal Transduction; Transplantation Conditioning; Vorinostat | 2016 |
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Bortezomib; Busulfan; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Membrane Potential, Mitochondrial; Middle Aged; Panobinostat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Lymphoma; Male; Melphalan; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Tumor Cells, Cultured | 2017 |
Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Count; Male; Melphalan; Recurrence; Retrospective Studies; Young Adult | 2017 |
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Cell Line, Tumor; Cytotoxins; Deoxycytidine; DNA Fragmentation; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Melphalan; Membrane Potential, Mitochondrial; Multiple Myeloma; Neoplasm Proteins; Panobinostat; Signal Transduction; Sulfonamides | 2020 |
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; Choroid Neoplasms; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Phenylacetates; Primary Cell Culture; Retinyl Esters; Tumor Cells, Cultured; Uveal Neoplasms; Valproic Acid | 2020 |
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Melphalan; Stem Cells; Transplantation Conditioning; Transplantation, Autologous | 2022 |